To evaluating the pharmacy response of the YTH family in liver cancer and renal cancer, we compared the RNA-sequencing expression in TCGA of YTHDF1 and YTHDF2 to the target-therapeutic response based on the largest publicly available pharmacogenomics database [the Genomics of Drug Sensitivity in Cancer (GDSC), https://www.cancerrxgene.org/]. This evidence concerns the gene YTHDF2 and liver cancer.